Post by Mehul Malhotra

Metastatic HER2-Positive Breast Cancer Market 2036: ADC Innovation and HER2-Targeted Therapies Redefine the Oncology Landscape  The #MetastaticHER2PositiveBreastCancerMarket across the 7MM is expected to witness significant growth through 2036, driven by regulatory approvals, late-stage clinical advancements, and an expanding pipeline of innovative targeted therapies, according to DelveInsight. Key Developments in #HER2PositiveBreastCancerResearch 📰:- 📊 In December 2025, the US FDA approved ENHERTU (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer, marking a significant advancement in frontline therapy. 🏢 In October 2025, Pfizer announced positive topline results from the Phase III HER2CLIMB-05 trial, demonstrating the potential of TUKYSA (tucatinib) as part of a first-line combination regimen for patients with HER2-positive metastatic breast cancer. 🧬 In December 2025, Pfizer presented detailed HER2CLIMB-05 Phase III findings at the San Antonio Breast Cancer Symposium (SABCS) and published the results in the Journal of Clinical Oncology, further strengthening the clinical evidence supporting TUKYSA in the maintenance treatment setting. 🚀 In March 2024, Johnson & Johnson completed the acquisition of Ambrx Biopharma, expanding its targeted oncology portfolio and advancing the development of the anti-HER2 antibody-drug conjugate ARX788 for HER2-positive cancers. Leading #HER2PositiveBreastCancer Companies include Byondis, Roche, Pfizer, Johnson & Johnson, Bolt Biotherapeutics, Inc., BioInvent International AB, Klus Pharma Inc., DualityBio, Artiva Biotherapeutics, Vaccinex, Suzhou Nanomicro Tech India, Dizal Pharmaceutical, Daiichi Sankyo US, AstraZeneca, Seagen, MacroGenics, Inc., and others. Explore DelveInsight's comprehensive report on the Metastatic HER2-Positive Breast Cancer Market Insights, Epidemiology, and Market Forecast – 2036 @ https://lnkd.in/dfz6xJaw #MetastaticHER2PositiveBreastCancer #HER2PositiveBreastCancer #BreastCancer #Oncology #AntibodyDrugConjugates #ADC #TargetedTherapy #ClinicalTrials #CancerResearch #PrecisionMedicine #DrugDevelopment #Biotech #Pharma #Healthcare #MarketResearch #DelveInsight #ENHERTU #TUKYSA #ARX788 #HER2CLIMB05